Cultivated meat M&A: Meatable buys Uncommon Bio platform

Meatable has acquired cultivated meat platform of UK start-up Uncommon Bio. Following its acquisition, the Dutch cultivated meat company has access to technology, cell lines, intellectual property assets and even staff expertise previously owned by Uncommon Bio. This means, according to Meatable, it is the only multi-platform cultivated meat company. Its new technology will accelerate the development of its cultivated lamb and chicken products. Furthermore, its regulatory-ready dossier may help Meatable boost regulatory approval. Meanwhile, patents and proprietary assets acquired from Uncommon help Meatable consolidate its position within the cultivated meat sector. Uncommon Bio started out as a cultivated meat company, but has recently began focusing on therapeutics. Thus, it wanted to find a new home for its cultivated meat arm. “This acquisition is more than a strategic step – it sets a new standard for cultivated meat production,” said Jeff Tripician, CEO of Meatable. “By combining two highly complementary platforms, Meatable is now equipped to reliably deliver high-quality cultivated meat at a global scale. This enables us to support the meat industry with a stable, secure, and future-proof supply of species like pork, beef, lamb, and poultry, ensuring business continuity and resilience in the face of increasingly uncertain times.” The company has in the past said that it wants to focus on assuaging the demand for animal meat , not replacing it. The cultivated meat space continues to see activity, despite scepticism from investors, bans from US states, and uncertainty from consumers.

Cultivated meat M&A: Meatable buys Uncommon Bio platform

The acquisition gives it access to staff, technology and intellectual property rights

Related Topics